RevolutionLogo.png
Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
September 30, 2021 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
RevolutionLogo.png
Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit
September 15, 2021 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
RevolutionLogo.png
Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
RevolutionLogo.png
Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress
August 11, 2021 16:01 ET | Revolution Medicines, Inc.
Company Shows Continued Progress Demonstrating Differentiation of RAS(ON) Inhibitors, Targeting Additional RAS Variants and Progressing Assets Toward the Clinic Initial Results of RMC-4630-02 Study...
RevolutionLogo.png
Revolution Medicines to Report Financial Results for Second Quarter 2021 After Market Close on August 11, 2021
August 04, 2021 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
RevolutionLogo.png
Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1
June 24, 2021 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit...
RevolutionLogo.png
Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors
June 10, 2021 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
RevolutionLogo.png
Revolution Medicines to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
June 02, 2021 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
RevolutionLogo.png
Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit
May 18, 2021 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
RevolutionLogo.png
Revolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress
May 10, 2021 16:05 ET | Revolution Medicines, Inc.
Multiple AACR Presentations Highlight Potential Advantages of RAS(ON) Inhibitors; Scientific Publication is First to Demonstrate Anti-Drug Resistance Features Continued Advancement and Enrollment of...